Abstract from ASCO Annual Meeting 2022
LBA7502: Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL) - Presented by Michael Wang.

Produced by the European Society for Medical Oncology
[ Ссылка ]

свернуть